文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

脊柱立体定向放射外科治疗患者中脑膜转移的早期检测

Early Detection of Leptomeningeal Metastases Among Patients Undergoing Spinal Stereotactic Radiosurgery.
PubMed 文献 · Adv Radiat Oncol · 2022-12-26

该单中心回顾性研究分析了2014至2019年495例因脊柱立体定向体部放疗(SBRT)计划行CT脊髓造影的转移性实体瘤患者,其中51例(10.3%)发生脑膜转移(LM),8例(1.6%)为亚临床LM。亚临床LM与临床显性LM的中位生存期相似(3.6 vs 3.0个月,P=0.30)。同时存在脑实质转移和LM的患者(29/51)生存期短于单纯LM患者(2.4 vs 7.1个月,P=0.02)。

要点

  • 脊柱SBRT计划CT脊髓造影时常规收集脑脊液,可通过细胞学检测亚临床LM。
  • 亚临床LM与临床显性LM的中位生存期相似(3.6 vs 3.0个月,P=0.30)。
  • 合并脑实质转移和LM患者生存期短于单纯LM患者(2.4 vs 7.1个月,P=0.02)。

核心结论

  • LM仍是转移性癌症的致命并发症。
  • 脊柱SBRT患者中通过脑脊液细胞学检测的亚临床LM与标准检测的LM预后相似,需考虑中枢神经系统导向治疗。
  • 随着局部激进治疗在转移患者中日益增多,更敏感的脑脊液评估可能进一步识别亚临床LM患者,应进行前瞻性评估。

研究设计与样本

  • 单中心回顾性分析2014至2019年495例接受脊柱SBRT计划CT脊髓造影的转移性实体瘤患者的临床记录。

主要发现

  • 计划SBRT患者中51例(10.3%)发生LM,其中8例(1.6%)为亚临床LM。
  • 亚临床LM与临床显性LM的中位生存期相似(3.6 vs 3.0个月,P=0.30)。
  • 合并脑实质转移和LM患者(29/51)生存期短于单纯LM患者(2.4 vs 7.1个月,P=0.02)。

临床怎么用

  • 作者认为,脊柱SBRT患者中经脑脊液细胞学检测的亚临床LM预后与标准检测的LM相似,需考虑中枢神经系统导向治疗。
  • 作者认为,更敏感的脑脊液评估可能进一步识别亚临床LM患者,应进行前瞻性评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The management of patients with advanced solid malignancies increasingly uses stereotactic body radiation therapy (SBRT). Advanced cancer patients are at risk for developing leptomeningeal metastasis (LM), a fatal complication of metastatic cancer. Cerebrospinal fluid (CSF) is routinely collected during computed tomography (CT) myelography for spinal SBRT planning, offering an opportunity for early LM detection by CSF cytology in the absence of radiographic LM or LM symptoms (subclinical LM). This study tested the hypothesis that early detection of tumor cells in CSF in patients undergoing spine SBRT portends a similarly poor prognosis compared with clinically overt LM. METHODS AND MATERIALS: We retrospectively analyzed clinical records for 495 patients with metastatic solid tumors who underwent CT myelography for spinal SBRT planning at a single institution from 2014 to 2019. RESULTS: Among patients planned for SBRT, 51 (10.3%) developed LM. Eight patients (1.6%) had subclinical LM. Median survival with LM was similar between patients with subclinical versus clinically evident LM (3.6 vs 3.0 months, P = .30). Patients harboring both parenchymal brain metastases and LM (29/51) demonstrated shorter survival than those with LM alone (2.4 vs 7.1 months, P = .02). CONCLUSIONS: LM remains a fatal complication of metastatic cancer. Subclinical LM detected by CSF cytology in spine SBRT patients has a similarly poor prognosis compared with standardly detected LM and warrants consideration of central nervous system-directed therapies. As aggressive local therapies are increasingly used for metastatic patients, more sensitive CSF evaluation may further identify patients with subclinical LM and should be evaluated prospectively.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Freret ME, Wijetunga NA, Shamseddine AA, et al. Early Detection of Leptomeningeal Metastases Among Patients Undergoing Spinal Stereotactic Radiosurgery. Adv Radiat Oncol. 2022. PMID: 36845624. doi:10.1016/j.adro.2022.101154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。